Oric Pharmaceuticals Inc (ORIC) - Total Liabilities
Based on the latest financial reports, Oric Pharmaceuticals Inc (ORIC) has total liabilities worth $21.20 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Oric Pharmaceuticals Inc - Total Liabilities Trend (2017–2025)
This chart illustrates how Oric Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. See ORIC net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Oric Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Oric Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Heritage Commerce Corp
NASDAQ:HTBK
|
USA | $5.06 Billion |
|
Ton Yi Industrial Corp
TW:9907
|
Taiwan | NT$11.22 Billion |
|
Shenzhen Sunnypol Optoelectronics Co Ltd
SHE:002876
|
China | CN¥3.95 Billion |
|
Amerigo Resources Ltd.
TO:ARG
|
Canada | CA$84.02 Million |
|
Abacus Life Inc.
NASDAQ:ABL
|
USA | $479.34 Million |
|
MBK Public Company Limited
BK:MBK
|
Thailand | ฿38.57 Billion |
|
Xencor Inc
NASDAQ:XNCR
|
USA | $243.50 Million |
|
Allmed Medical Products Co Ltd Class A
SHE:002950
|
China | CN¥2.18 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down Oric Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Oric Pharmaceuticals Inc (ORIC) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 16.33 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Oric Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Oric Pharmaceuticals Inc (2017–2025)
The table below shows the annual total liabilities of Oric Pharmaceuticals Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $26.64 Million | -14.12% |
| 2024-12-31 | $31.02 Million | +1.38% |
| 2023-12-31 | $30.60 Million | +9.25% |
| 2022-12-31 | $28.01 Million | +9.12% |
| 2021-12-31 | $25.67 Million | +178.34% |
| 2020-12-31 | $9.22 Million | +50.69% |
| 2019-12-31 | $6.12 Million | -94.50% |
| 2018-12-31 | $111.16 Million | +2485.72% |
| 2017-12-31 | $4.30 Million | -- |
About Oric Pharmaceuticals Inc
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target… Read more